Novartis Sues To Protect Market For Epilepsy Drug
The lawsuit targets Haifa Bay, Israel-based Taro Pharmaceutical Industries Ltd. and its U.S. subsidiary, and alleges that the defendants infringed a Novartis patent when they filed an Abbreviated New Drug Application seeking approval to make and sell generic oxacarbazepine—Trileptal’s active ingredient.
At issue is U.S. Patent No. 7,037,525,...
To view the full article, register now.